View Article

Abstract

Diabetes mellitus is a group of common endocrine diseases characterized by sustained high blood sugar levels and physiological dysfunctions characterized by hyper-glycemia resulting directly from insulin resistance, inadequate insulin secretion, or excessive glucagon secretion. Commonly reported manifestations are Polydipsia, Polyuria, Polyphagia, Weight loss, etc. Diabetes mellitus classification is Type 1 diabetes (T1D) is an autoimmune disorder leading to the destruction of pancreatic beta-cells. Type 2 diabetes (T2D), which is much more common, is primarily a problem of progressively impaired glucose regulation due to a combination of dysfunctional pancreatic beta cells and insulin resistance. The purpose of this article is to review the basic science of type 2 diabetes and its complications, and to discuss the most recent treatment.

Keywords

Diabetes mellitus, Insulin, Disorder, Treatment

Introduction

A metabolic disease called diabetes mellitus is typified by elevated blood glucose levels brought on by a malfunctioning or relative lack of insulin secretion. Chronic hyperglycaemia is linked to an increased risk of cardiovascular disease (CVD) and relatively specific long-term microvascular consequences that affect the kidneys, nerves, and eyes. The bloodstream is responsible for delivering glucose to the body's cells, which need it as a food source. However, without the hormone insulin, they are unable to absorb and use glucose. However, without the hormone insulin, they are unable to absorb and use glucose. The pancreas produces this hormone, insulin. Insulin functions similarly to a key that opens the door to separate our blood sugars from cells. The hallmark of diabetes mellitus is a disruption in the metabolism of fat, protein, and carbohydrates brought on by a total or partial lack of insulin action and/or secretion.[1] In the context of insulin resistance, diabetes is a complicated, long-term condition marked by inadequate β-cell insulin production. One of the biggest challenges to global health today is diabetes, which ranks among the top three noncommunicable diseases and is responsible for more than 80% of all early deaths from noncommunicable diseases. It is also one of the top 10 causes of mortality globally. Its widespread occurrence worldwide. Its global prevalence has rapidly increased over the past several decades.[2]

Fig no. 1. Elevation of blood glucose

Risk factors for Diabetes mellitus:

  • Insulin resistance
  • Age
  • Weight
  • Diet
  • Family history

Symptoms of Diabetes mellitus:

  • Polydipsia (Feeling thirstier)
  • Polyuria (Urinating a lot)
  • Bed-wetting in children who have never wet the bed during the night
  • Polyphagia (Feeling very hungry)
  • Weight loss
  • Feeling irritable or having other mood changes
  • Feeling tired and weak
  • Blurry vision
  1. Pathophysiology of Diabetes:

A healthy physiological state is created and maintained by the coordinated action of several systems and pathways in the human body. The ability of the body to maintain homeostasis, or a steady, stable condition, is at the heart of these processes. In different organs, an injury or diseased state develops as a result of an imbalance in homeostasis. Diabetes mellitus. impairs a person's capacity to control blood glucose levels, which can lead to a number of serious and moderate problems. [4,13]

  1. Types Of Diabetes Mellitus:
  1. Hormone Dependent diabetes (Type ? IDDM)

The chronic illness known as type I diabetes mellitus (T1DM) is typified by the body's incapacity to manufacture insulin as a result of the autoimmune destruction of the pancreatic beta cells. It causes hyperglycaemia. This kind was once known as "juvenile diabetes" or "insulin-dependent diabetes mellitus" (IDDM).[3] According to the International Diabetes Federation, 8.8% of the adult population globally has diabetes14. kind 2 diabetes mellitus (T2DM) is the most prevalent kind of diabetes, with only 10–15% of those with diabetes having T1DM. Nonetheless, T1DM is the most prevalent type of diabetes in children, affecting 500,000 children worldwide at the moment.[5]

Risk factor for type I Diabetes mellitus:

  • Family history: Having a parent, brother, or sister with type 1 diabetes.
  • Age: Diabetes mellitus is a condition that can developed at any age, but it usually develops in children, teens, or young adult.

Symptoms of type I Diabetes mellitus:

  • Polydipsia (excessive thirst)
  • Polyuria (Urinating a lot)
  • Polyphagia (Feeling very hungry)
  • Weight loss
  • Feeling irritable or having other mood changes
  • Feeling tired and weak
  • Blurry vision
  1. Non-Insulin Dependent polygenic disorder Mellitus (Type ? NIDPDM)

insulin resistance as a backdrop for the increasing insulin secretary malfunction. Insulin resistance is a common feature of this kind of diabetes. This kind was once known as "adult-onset diabetes" or "non-insulin-dependent diabetes mellitus" (NIDDM). Being overweight and not exercising enough are the main causes. The body produces insulin when insulin resistance occurs, however insulin sensitivity is decreased and the insulin does not function as well as it should.[5] Two issues result from the glucose's improper entry into the body's cells: • An accumulation of glucose in the blood; and • The cells' inability to get the glucose required for growth and energy. Type 2 diabetes is a worldwide health crisis. In the U.S., 20.8 million are affected at a cost of 2 billion in 2002, and the numbers will likely continue to increase. The Centres for Disease Control and Prevention estimates there are more than 40 million people in the U.S. with prediabetes. Given that the Diabetes Prevention Program showed an 11% yearly conversion rate of impaired glucose tolerance (IGT) to diabetes, there could be as many as 4 million new cases each year. Furthermore, the incidence of type 2 diabetes is rising around the world, with a recent prediction that the worldwide prevalence will increase from 2.8% in 2000 to 4.4% in 2030, resulting in 366 million affected people. [6]

Risk factor for type ? Diabetes mellitus:

  • Obesity
  • Family history and genetics

Symptoms of type ? Diabetes mellitus:

  • Polyuria
  • Blurry vision
  • Polydipsia
  • Fatigue
  • Peripheral neuropathy
  • Slow healing wound
  1. Gestational diabetes

Gestational diabetes mellitus (GDM) is the term used to describe glucose intolerance that is discovered or first experienced during pregnancy. Pregnant women with undetected asymptomatic Type 2 diabetes mellitus and those who develop Type 1 diabetes mellitus are both considered to have gestational diabetes mellitus (GDM). In gestational diabetes mellitus (GDM), a hormone produced by the placenta interferes with the body's ability to use insulin. Rather than being absorbed by the cells, glucose accumulates in the circulation.[7]

Risk factor for gestational Diabetes mellitus:

  • Overweight or obesity
  • Family history of diabetes
  • Having given birth previously to an infant weighing greater than 9 pounds
  • Age (women who are older than 25 are at a greater risk for developing gestational           diabetes than younger women)
  • Race (women who are African-American, American Indian, Asian American, Hispanic or Latino, or Pacific Islander have a higher risk).

Symptoms of gestational Diabetes mellitus:

  • Polydipsia
  • Polyuria
  1. The worldwide epidemiology of Type ? Diabetes mellitus:

Over the previous three decades, the number of people with diabetes mellitus has more than doubled globally.2. Type 2 diabetes mellitus (T2DM) accounted for 90% of the estimated 285 million individuals with diabetes mellitus globally in 2010.One By 2030, it is anticipated that 439 million people worldwide would have diabetes mellitus, accounting for 7.7% of all adults aged 20 to 79 nationwide.[8]

Fig no. 2: In each box, the top and middle values represent the number of people with diabetes mellitus (in millions) in each of seven world regions (depicted with different colours) for 2010 and 2030, respectively; the bottom value is the percentage increase from 2010 to 2030. The number of people globally with diabetes mellitus is projected to rise from 285 million in 2010 to 439 million by 2030, a 54% increase.

Fig no. 3: The number of people with diabetes mellitus and IGT (in millions) by region among adults aged 20–79 years for the years 2010 and 2030. Data courtesy of the International Diabetes Federation Diabetes Atlas.114 Abbreviation: IGT, impaired glucose tolerance.

  1. Diagnosis test of Diabetes mellitus:
  1. A1C LEVEL:

The proportion of glycosylation of the haemoglobin A1C chain is known as A1C, and it roughly represents the average blood glucose levels throughout the preceding two to three months due to the body's gradual red blood cell turnover.[9]

Table no.1: Glucose level in A1C test.

Diagnosis

A1C

Normal

Below 5.7%

Prediabetes

5.7 to 6.4%

Diabetes

6.5% or above

  1. Fasting blood glucose test (F.B.G.T):

For at least eight hours prior to the test, you should only consume water (fast) and nothing else. Blood sugar can be significantly impacted by food. Your provider can view your baseline blood sugar levels with this test.[10]

Table no.2: Glucose level in Fasting blood glucose test.

Diagnosis

Range

Normal

Less than 99 mg/dL (decilitre)

Prediabetes

100 to 125 mg/dL

Diabetes

126mg/dL or higher

  1. Oral glucose tolerance test (O.G.T.T.):

The ability of the body to absorb, utilize, and eliminate glucose from the bloodstream is measured by the oral glucose tolerance test (OGTT). It is safe for both adults and children and is also known as a glucose tolerance test. You don't eat for a time before doing the test, and then you sip a syrupy solution. To find out how your body is responding to the sugar in the beverage, a few blood samples are drawn.[11]

Table no.3: Glucose level in Oral glucose tolerance test.

Diagnosis

Oral glucose tolerance test

Normal

139mg/dL or below (decilitre)

Prediabetes

140 to 199 mg/dL

Diabetes

  1. /dL or higher
  1. Random plasma glucose test (R.P.G.T):

When you exhibit signs of diabetes and your doctor does not want to wait until you have fasted for eight hours, they may perform the random plasma glucose test to make the diagnosis. This blood test can be performed at any time.[12] When blood glucose levels are 200 mg/dL or higher, diabetes is diagnosed.

  1. Treatments of Type ? Diabetes Mellitus:

Currently, there are many different ways to manage diabetes mellitus. It may be difficult for the doctors to find the proper combination. Doctors choose the appropriate course of treatment based on the type and severity of diabetes mellitus.

Different treatment options for Diabetes Mellitus;

  • Healthy eating.
  • Regular exercise.
  • Weight loss.
  • Blood sugar monitoring.
  • Non-insulin Diabetes medication.
  • Novel drug delivery system for antidiabetic drugs for T2DM
  1. Healthy eating:

There's no specific diabetes diet. However, it's important to centre your diet around:

  • A regular schedule for meals and healthy snacks.
  • Smaller portion sizes.
  • More high-fibres foods, such as fruits, no starchy vegetables and whole grains.
  • Fewer refined grains, starchy vegetables and sweets.
  • Modest servings of low-fat dairy, low-fat meats and fish.
  • Healthy cooking oils, such as olive oil or canola oil.
  • Fewer calories.
  1. Physical activity:

Maintaining a healthy weight or reducing weight requires exercise. It also helps with managing blood sugar. Before beginning or altering your exercise regimen, consult your healthcare professional to be sure the activities are safe for you.

  • Aerobic exercise. 
  • Resistance exercise. 
  • Limit inactivity
  1. Weight loss:

Losing weight improves blood pressure, cholesterol, triglycerides, and blood sugar regulation. After lowering even 5% of your body weight, overweight people may start to notice changes in these areas. However, the health benefits increase with the amount of weight you reduce. It may be advised in certain situations to reduce body weight by up to 15%.

  1. Monitoring your blood sugar:

To ensure that you stay within your goal range, your healthcare practitioner will advise you on how frequently to check your blood sugar level. For instance, you might need to check it once daily and either before or after working out. You might need to check your blood sugar several times a day if you use insulin.

  1. Non-insulin treatment:

A number of non-insulins based oral therapies have emerged for the treatment of type 2 DM. These are categorized under the following sub-headings [14].

  1. Herbal Medicines
  2. Insulin Secretagogues
  3. Biguanides
  4. Insulin Sensitizers
  5. Alpha Glucosidase Inhibitors
  6. Amylin antagonists
  7. SGLT2 inhibitors
  1. Herbal Medicines:

Several plant extracts were tested to corroborate their synergistic and multifactorial acts towards DM. Here are represented a few of those [15].

Table no.4: Herbal drug for treatment of Type ? D.M.:

Drug

Activity

  1. Momordica Charantia

The increased expression of PPAR-y and reduced leptin expression in white adipose tissues, as well as the promotion of GLUT4 expression in skeletal muscles. Regardless the mechanisms, its extracts improved insulin sensitivity, glucose tolerance and insulin signalling pathway [16].

  1. Panax Ginseng

saponin and polysaccharide constituents which might be involved in the double activation of AMP-activated protein kinase (AMPK) and PPAR- y [17]. They act with different mechanisms including the stimulation of insulin biosynthesis and its secretion. Furthermore, consumption of ginseng increases insulin-regulated receptor (GLUT-4) in skeletal muscle and in liver and increases lipoprotein lipase (LPL) and PPAR-in adipose tissues [18].

  1. Trigonella Foenum-Graecum

Inhibit carbohydrate metabolic enzymes leading to hypoglycaemic effects. Furthermore, its seeds can decrease glucose-6-phosphatase and fructose-1,6-bisphosphatase in liver and kidney [19].

  1. Scutellariae Radix

Improvement in insulin resistance and the suppression of gluconeogenesis.

  1. Coptidis Rhizoma

Lower blood glucose and promoting the secretion of insulin.

  1. Insulin Secretagogues:

By attaching to the sulfonylurea receptor (SUR) of the ATP-sensitive potassium channel on pancreatic β cells, these medications—particularly sulfonyl urea’s and metiglinides—increase the amount of insulin secreted by the pancreas. [20]

Table no.5: Insulin Secretagogues drug for treatment of Type ? D.M.:

Drugs

Side effect

  1. 1st generation sulfonylurea;

Tolbutamide

Chlorpropamide

Tolazamide

Aceto-hexamide [21]

  1. 2nd generation sulfonylurea;

Glibenclamide

Glipizide

Glimepiride [21]

Low blood sugar level

Dizziness

Sweating

Confusion

Nervousness [22]

Hunger

Weight gain

Skin reaction

Stomach upset

Dark coloured urine.

  1. Biguanides:

It functions by enhancing the body's reaction to natural insulin, lowering intestinal glucose absorption, and lowering the quantity of glucose the liver produces. By promoting glycolysis and inhibiting gluconeogenesis, biguanides lower the amount of glucose produced by the liver. By raising insulin receptor activation, they raise insulin signalling.[23]

Table no.6: Biguanides drug for treatment of Type ? D.M.:

Drugs

Side effect

Metformin

Phenformin

Buformin

  • Diarrhoea
  • Cramps
  • Nausea
  • Vomiting
  • increased flatulence
  • Its Long-term use is associated with decreased absorption of vitamin B 12 [24]
  1. Insulin Sensitizers:

Another name for the insulin sensitizers is PPARs, or peroxisome proliferator activated receptor agonists. PPARs control the metabolism of proteins and carbohydrates and preserve glucose homeostasis. These are ligand-activated transcription factors that belong to the nuclear hormone receptor superfamily [25].

Table no.7: Insulin Sensitizers drug for treatment of Type ? D.M.:

Drug

Primary tissue target

Mechanism of action

Side effect

  1. Metformin

liver

Inhibition of hepatic glucose output/insulin sensitivity.

  • Diarrhoea
  • Cramps
  • Nausea
  • Vomiting
  • Increased flatulence
  • Its Long-term use is associated with decreased absorption of vitamin B 12 [24]
  1. PPAR-y agonists;

Pioglitazone

Rosiglitazone

Ciglitazone

Adipose, muscle & liver

Insulin-sensitising/anti- inflammatory.

  • Edema
  • Weight gain
  • Macular edema
  • Heart failure [28]
  1. PPAR-y/a dual agonists;

Muraglitizar Tesaglitazar Aleglitazar Ragaglitizar Naveglitazar  Saroglitazar[27]

Adipose, muscle & liver [26]

Insulin-sensitising, anti- inflammatory & lipid lowering.

  • Cardiotoxicity
  1. Dipeptidyl peptidase IV inhibitors;

Sitagliptin

Saxagliptin linagliptin

Pancreatic ? cells.

Stimulation of insulin release and B-cell differentiation [26].

  • Pancreatitis or kidney disease
  1. Alpha Glucosidase Inhibitors:

By shifting the undigested carbohydrate toward the distal portion of the small intestine and colon, AGIs slow down the process of carbohydrate absorption in the gastrointestinal tract and assist lower postprandial hyperglycaemia [29].

Table no.8: Alpha Glucosidase Inhibitors drug for treatment of Type ? D.M.:

Drugs

Side effect

Valises

Miglitol [30]

  • Bloating,
  • Flatulence
  • Gastrointestinal irritation [31]
  1. Amylin antagonists:

A single chain of 37 amino acids makes up the hormone amylin. It is co-secreted by the pancreatic β cells together with insulin. It keeps blood glucose levels stable during fasting and after meals by delaying stomach emptying and inhibiting glucagon secretion. By altering the brain's appetite centre, it controls how much food is consumed [32].

Table no.9: Amylin antagonists’ drug for treatment of T ? D.M.:

Drugs

Side effect

Pramlintide acetate

  • Nausea
  • Vomiting
  • Headache
  • Hypoglycaemia [33]
  1. Sodium glucose co-transporter ? inhibitors (SGLT2):

Reabsorption of glucose in proximal convoluted tubule (PCT) is done by transporter, sodium glucose co-transporter (SGLT) [34]. SGLT2 inhibitors suppress the SGLT2 found in PCT which limits reabsorption of glucose and improves the elimination of glucose in urine. As glucose is eliminated in urine, the glucose level in the blood is maintained and other glycaemic parameters are maintained [35].

Table no.10: Sodium glucose co-transporter 2 inhibitors drug for treatment of Type ? D.M.:

Drug

Side effect

Canagliflozin

Dapagliflozin

Empagliflozin

Ipragliflozin

Luseogliflozin

Tofogliflozin [36].

  • Ketoacidosis
  • Genital infections
  1. Novel drug delivery system for antidiabetic drugs:

Some drawbacks of traditional drug delivery methods include reduced potency or altered effects as a result of drug metabolism, lack of target specificity, and ineffectiveness due to incorrect or ineffective dosage [37, 38]. Because of its advantages in lowering the frequency of doses, improving bioavailability, preventing degradation in an acidic stomach environment, and providing tailored therapeutic efficacy with fewer side effects, novel drug delivery systems (NDDSs) have become one of the newest and most promising topics in recent years [39].

Table no.11: Novel drug delivery system drug for treatment of Type ? D.M.:

Type of delivery system

Class of drug

Name of drug

Liposome

Biguanides

Metformin

Incretin Mimetics

 

Glucagon-like peptide-1 (GLP- 1)

Liraglutide [40]

Sulfonylureas

Gliclazide

Insulin Secretagogues

Repaglinide [41]

Niosome

Biguanides

Metformin [42]

Insulin Sensitizers – Thiazolidinediones

Pioglitazone

 

Insulin Secretagogues

Repaglinide [43]

Polymeric Nanoparticles

Biguanides

Metformin

 

Sulfonylureas

 

Glipizide

Glimepiride

Glibenclamide

Insulin Sensitizers – Thiozolidinediones

Pioglitazone [44]

Insulin Secretagogues

Repaglinide

Nano-emulsion

Insulin Secretagogues

Repaglinide

Insulin Sensitizers – Thiazolidinediones

Pioglitazone

 

Self-nano-emulsifying drug delivery systems

Sulfonylureas

 

Glipizide

Glimepiride

Glibenclamide

Insulin Secretagogues

Repaglinide

Carbon Nanotubes

Biguanides

Metformin

Nanocrystal

Sulfonylureas

Gliclazide

Nano-formulations in Transdermal patches (TDPs)

Biguanides

Metformin

Sulfonylureas

Glimepiride

Insulin Secretagogues

Repaglinide [45]

CONCLUSION:

Type ? DM is a metabolic disease that can be prevented through lifestyle modification, diet control, control of overweight, obesity and the medication. Education of the population is still key to the control of this emerging epidemic. Novel drugs are being developed, yet no cure is available in sight for the disease, despite new insight into the pathophysiology of the disease. Management should be tailored to improve the quality of life of individuals with type ? DM.

REFERENCES

  1. Tripathi BK, Srivastava AK. Diabetes mellitus: complications and therapeutics. Med Sci Monit. 2006 Jul 1;12(7):130-47.
  2. Hu C, Jia W. Therapeutic medications against diabetes: what we have and what we expect. Advanced Drug Delivery Reviews. 2019 Jan 15; 139:3-15.
  3. Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 diabetes mellitus and autoimmune diseases: a critical review of the association and the application of personalized medicine. Journal of Personalized Medicine. 2023 Feb 26;13(3):422.
  4. Kaul K, Tarr JM, Ahmad SI, Kohner EM, Chibber R. Introduction to diabetes mellitus. Diabetes: an old disease, a new insight. 2013:1-1.
  5. Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, Jacobsen LM, Schatz DA, Lernmark Å. Type 1 diabetes mellitus. Nature reviews Disease primers. 2017 Mar 30;3(1):1-7.
  6. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Archives of medical research. 2005 May 1;36(3):197-209.
  7. Singh N, Kesherwani R, Tiwari AK, Patel DK. A review on diabetes mellitus. The Pharma Innovation. 2016 Jul 1;5(7, Part A):36.
  8. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nature reviews endocrinology. 2012 Apr;8(4):228-36.  (vancover)
  9. Cohen RM, Haggerty S, Herman WH. HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction?. The Journal of Clinical Endocrinology & Metabolism. 2010 Dec 1;95(12):5203-6.
  10. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes care. 2015 Jan 1;38(Supplement_1):S8-16.
  11. American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee:. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022. Diabetes care. 2022 Jan 1;45(Supplement_1):S17-38.
  12. Care D. 13. Older Adults: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022 Jan 1;45:S195.
  13. Okur ME, Karantas ID, Siafaka PI. Diabetes Mellitus: a review on pathophysiology, current status of oral pathophysiology, current status of oral medications and future perspectives. ACTA Pharmaceutica Sciencia. 2017;55(1).
  14. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug-based therapeutics. Biomedicine & Pharmacotherapy. 2020 Nov 1; 131:110708.
  15. Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020 Apr 23;25(8):1987.
  16. Sridhar MG, Vinayagamoorthi R, Suyambunathan VA, Bobby Z, Selvaraj N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. British Journal of Nutrition. 2008 Apr;99(4):806-12.
  17. Lee HJ, Lee YH, Park SK, Kang ES, Kim HJ, Lee YC, Choi CS, Park SE, Ahn CW, Cha BS, Lee KW. Korean red ginseng (Panax ginseng) improves insulin sensitivity and attenuates the development of diabetes in Otsuka Long-Evans Tokushima fatty rats. Metabolism. 2009 Aug 1;58(8):1170-7.
  18. Mollah ML, Kim GS, Moon HK, Chung SK, Cheon YP, Kim JK, Kim KS. Antiobesity effects of wild ginseng (Panax ginseng CA Meyer) mediated by PPAR?γ, GLUT4 and LPL in ob/ob mice. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2009 Feb;23(2):220-5.
  19. Ernst, E. Major Herbs of Ayurveda. Focus Altern. Complement. Ther. 2010, 8, 98.
  20. Seino S, Sugawara K, Yokoi N, Takahashi H. β?Cell signalling and insulin secretagogues: A path for improved diabetes therapy. Diabetes, Obesity and Metabolism. 2017 Sep; 19:22-9.
  21. Kalra S, Bahendeka S, Sahay R, Ghosh S, Md F, Orabi A, Ramaiya K, Al Shammari S, Shrestha D, Shaikh K, Abhayaratna S. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus–International Task Force. Indian journal of endocrinology and metabolism. 2018 Jan 1;22(1):132-57.
  22. Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, Corlianò F, Fra GP, Bartoli E, Derosa G. State of the art paper Sulfonylureas and their use in clinical practice. Archives of medical science. 2015 Aug 10;11(4):840-8.
  23. Quillen DM, Samraj G, Kuritzky L. Improving management of type 2 diabetes mellitus: 2. Biguanides. Hospital Practice. 1999 Oct 15;34(11):41-4.
  24. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017 Sep;60:1586-93.
  25. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. Journal of advanced pharmaceutical technology & research. 2011 Oct 1;2(4):236-40.
  26. Tadayyon M, Smith SA. Insulin sensitisation in the treatment of Type 2 diabetes. Expert opinion on investigational drugs. 2003 Mar 1;12(3):307-24.
  27. Balakumar P, Mahadevan N, Sambathkumar R. A contemporary overview of PPARα/γ dual agonists for the management of diabetic dyslipidemia. Current Molecular Pharmacology. 2019 Aug 1;12(3):195-201.
  28. Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Current diabetes reports. 2019 Dec;19(12):151.
  29. Alpha-Glucosidase Inhibitors for Diabetes, Precose & Glyset for Type 2 Diabetes, 2019 (assessed 21 December 2019), https://www.webmd.com/diabetes/alpha-gl ucosidase-inhibitors-diabetes.
  30. Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, Fujita H, Tsukiyama K, Yamada Y. Comparisons of the effects of 12?week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes, Obesity and Metabolism. 2012 Mar;14(3):283-7.
  31. Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Archives of medical science: AMS. 2012 Nov 11;8(5):899.
  32. Adeghate E, Kalász H. Suppl 2: amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. The open medicinal chemistry journal. 2011;5:78.
  33. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes. 2004 Dec 1;53(suppl_3):S233-8.
  34. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity. 2017 Feb 1;24(1):73-9.
  35. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015 Jan;75:33-59.
  36. Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. International journal of environmental research and public health. 2019 Aug;16(16):2965.
  37. DiSanto RM, Subramanian V, Gu Z. Recent advances in nanotechnology for diabetes treatment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2015 Jul;7(4):548-64.
  38. Dash TK, Konkimalla VB. Poly-?-caprolactone based formulations for drug delivery and tissue engineering: A review. Journal of Controlled Release. 2012 Feb 28;158(1):15-33.
  39. Rai VK, Mishra N, Agrawal AK, Jain S, Yadav NP. Novel drug delivery system: an immense hope for diabetics. Drug delivery. 2016 Sep 1;23(7):2371-90.
  40. Zhang L, Ding L, Tang C, Li Y, Yang L. Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes. Drug delivery. 2016 Nov 21;23(9):3358-63.
  41. Namdev S, Gujar K, Mandlik S, Jamkar P. Preparation and in vivo characterization of niosomal carriers of the antidiabetic drug repaglinide. International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN). 2015 Feb 28;8(1):2756-67.
  42. Hasan AA, Madkor H, Wageh S. Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. Drug delivery. 2013 Apr 1;20(3-4):120-6.
  43. Ebrahimi HA, Javadzadeh Y, Hamidi M, Jalali MB. Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles. DARU Journal of Pharmaceutical Sciences. 2015 Dec;23:1-1.
  44. Appana Chowdary K, Suravarapu NL, Meddala S. Formulation and characterization of pioglitazone hydrochloride nanoparticles. World Journal of Pharmacy and Pharmaceutical Sciences. 2015 Feb 19;4(04):1638-48.
  45. Vijayan V, Jayachandran E, Anburaj J, Rao DS, Kumar KJ. Transdermal delivery of repaglinide from solid lipid nanoparticles in diabetic rats: in vitro and in vivo studies. Journal of Pharmaceutical Sciences and Research. 2011 Mar 1;3(3):1077.

Reference

  1. Tripathi BK, Srivastava AK. Diabetes mellitus: complications and therapeutics. Med Sci Monit. 2006 Jul 1;12(7):130-47.
  2. Hu C, Jia W. Therapeutic medications against diabetes: what we have and what we expect. Advanced Drug Delivery Reviews. 2019 Jan 15; 139:3-15.
  3. Popoviciu MS, Kaka N, Sethi Y, Patel N, Chopra H, Cavalu S. Type 1 diabetes mellitus and autoimmune diseases: a critical review of the association and the application of personalized medicine. Journal of Personalized Medicine. 2023 Feb 26;13(3):422.
  4. Kaul K, Tarr JM, Ahmad SI, Kohner EM, Chibber R. Introduction to diabetes mellitus. Diabetes: an old disease, a new insight. 2013:1-1.
  5. Katsarou A, Gudbjörnsdottir S, Rawshani A, Dabelea D, Bonifacio E, Anderson BJ, Jacobsen LM, Schatz DA, Lernmark Å. Type 1 diabetes mellitus. Nature reviews Disease primers. 2017 Mar 30;3(1):1-7.
  6. Leahy JL. Pathogenesis of type 2 diabetes mellitus. Archives of medical research. 2005 May 1;36(3):197-209.
  7. Singh N, Kesherwani R, Tiwari AK, Patel DK. A review on diabetes mellitus. The Pharma Innovation. 2016 Jul 1;5(7, Part A):36.
  8. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. Nature reviews endocrinology. 2012 Apr;8(4):228-36.  (vancover)
  9. Cohen RM, Haggerty S, Herman WH. HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction?. The Journal of Clinical Endocrinology & Metabolism. 2010 Dec 1;95(12):5203-6.
  10. American Diabetes Association. 2. Classification and diagnosis of diabetes. Diabetes care. 2015 Jan 1;38(Supplement_1):S8-16.
  11. American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee:. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022. Diabetes care. 2022 Jan 1;45(Supplement_1):S17-38.
  12. Care D. 13. Older Adults: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2022 Jan 1;45:S195.
  13. Okur ME, Karantas ID, Siafaka PI. Diabetes Mellitus: a review on pathophysiology, current status of oral pathophysiology, current status of oral medications and future perspectives. ACTA Pharmaceutica Sciencia. 2017;55(1).
  14. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug-based therapeutics. Biomedicine & Pharmacotherapy. 2020 Nov 1; 131:110708.
  15. Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020 Apr 23;25(8):1987.
  16. Sridhar MG, Vinayagamoorthi R, Suyambunathan VA, Bobby Z, Selvaraj N. Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. British Journal of Nutrition. 2008 Apr;99(4):806-12.
  17. Lee HJ, Lee YH, Park SK, Kang ES, Kim HJ, Lee YC, Choi CS, Park SE, Ahn CW, Cha BS, Lee KW. Korean red ginseng (Panax ginseng) improves insulin sensitivity and attenuates the development of diabetes in Otsuka Long-Evans Tokushima fatty rats. Metabolism. 2009 Aug 1;58(8):1170-7.
  18. Mollah ML, Kim GS, Moon HK, Chung SK, Cheon YP, Kim JK, Kim KS. Antiobesity effects of wild ginseng (Panax ginseng CA Meyer) mediated by PPAR?γ, GLUT4 and LPL in ob/ob mice. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives. 2009 Feb;23(2):220-5.
  19. Ernst, E. Major Herbs of Ayurveda. Focus Altern. Complement. Ther. 2010, 8, 98.
  20. Seino S, Sugawara K, Yokoi N, Takahashi H. β?Cell signalling and insulin secretagogues: A path for improved diabetes therapy. Diabetes, Obesity and Metabolism. 2017 Sep; 19:22-9.
  21. Kalra S, Bahendeka S, Sahay R, Ghosh S, Md F, Orabi A, Ramaiya K, Al Shammari S, Shrestha D, Shaikh K, Abhayaratna S. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus–International Task Force. Indian journal of endocrinology and metabolism. 2018 Jan 1;22(1):132-57.
  22. Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, Corlianò F, Fra GP, Bartoli E, Derosa G. State of the art paper Sulfonylureas and their use in clinical practice. Archives of medical science. 2015 Aug 10;11(4):840-8.
  23. Quillen DM, Samraj G, Kuritzky L. Improving management of type 2 diabetes mellitus: 2. Biguanides. Hospital Practice. 1999 Oct 15;34(11):41-4.
  24. Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia. 2017 Sep;60:1586-93.
  25. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. Journal of advanced pharmaceutical technology & research. 2011 Oct 1;2(4):236-40.
  26. Tadayyon M, Smith SA. Insulin sensitisation in the treatment of Type 2 diabetes. Expert opinion on investigational drugs. 2003 Mar 1;12(3):307-24.
  27. Balakumar P, Mahadevan N, Sambathkumar R. A contemporary overview of PPARα/γ dual agonists for the management of diabetic dyslipidemia. Current Molecular Pharmacology. 2019 Aug 1;12(3):195-201.
  28. Lebovitz HE. Thiazolidinediones: the forgotten diabetes medications. Current diabetes reports. 2019 Dec;19(12):151.
  29. Alpha-Glucosidase Inhibitors for Diabetes, Precose & Glyset for Type 2 Diabetes, 2019 (assessed 21 December 2019), https://www.webmd.com/diabetes/alpha-gl ucosidase-inhibitors-diabetes.
  30. Narita T, Yokoyama H, Yamashita R, Sato T, Hosoba M, Morii T, Fujita H, Tsukiyama K, Yamada Y. Comparisons of the effects of 12?week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients. Diabetes, Obesity and Metabolism. 2012 Mar;14(3):283-7.
  31. Derosa G, Maffioli P. α-Glucosidase inhibitors and their use in clinical practice. Archives of medical science: AMS. 2012 Nov 11;8(5):899.
  32. Adeghate E, Kalász H. Suppl 2: amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. The open medicinal chemistry journal. 2011;5:78.
  33. Schmitz O, Brock B, Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes. 2004 Dec 1;53(suppl_3):S233-8.
  34. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Current Opinion in Endocrinology, Diabetes and Obesity. 2017 Feb 1;24(1):73-9.
  35. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015 Jan;75:33-59.
  36. Tentolouris A, Vlachakis P, Tzeravini E, Eleftheriadou I, Tentolouris N. SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects. International journal of environmental research and public health. 2019 Aug;16(16):2965.
  37. DiSanto RM, Subramanian V, Gu Z. Recent advances in nanotechnology for diabetes treatment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology. 2015 Jul;7(4):548-64.
  38. Dash TK, Konkimalla VB. Poly-?-caprolactone based formulations for drug delivery and tissue engineering: A review. Journal of Controlled Release. 2012 Feb 28;158(1):15-33.
  39. Rai VK, Mishra N, Agrawal AK, Jain S, Yadav NP. Novel drug delivery system: an immense hope for diabetics. Drug delivery. 2016 Sep 1;23(7):2371-90.
  40. Zhang L, Ding L, Tang C, Li Y, Yang L. Liraglutide-loaded multivesicular liposome as a sustained-delivery reduces blood glucose in SD rats with diabetes. Drug delivery. 2016 Nov 21;23(9):3358-63.
  41. Namdev S, Gujar K, Mandlik S, Jamkar P. Preparation and in vivo characterization of niosomal carriers of the antidiabetic drug repaglinide. International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN). 2015 Feb 28;8(1):2756-67.
  42. Hasan AA, Madkor H, Wageh S. Formulation and evaluation of metformin hydrochloride-loaded niosomes as controlled release drug delivery system. Drug delivery. 2013 Apr 1;20(3-4):120-6.
  43. Ebrahimi HA, Javadzadeh Y, Hamidi M, Jalali MB. Repaglinide-loaded solid lipid nanoparticles: effect of using different surfactants/stabilizers on physicochemical properties of nanoparticles. DARU Journal of Pharmaceutical Sciences. 2015 Dec;23:1-1.
  44. Appana Chowdary K, Suravarapu NL, Meddala S. Formulation and characterization of pioglitazone hydrochloride nanoparticles. World Journal of Pharmacy and Pharmaceutical Sciences. 2015 Feb 19;4(04):1638-48.
  45. Vijayan V, Jayachandran E, Anburaj J, Rao DS, Kumar KJ. Transdermal delivery of repaglinide from solid lipid nanoparticles in diabetic rats: in vitro and in vivo studies. Journal of Pharmaceutical Sciences and Research. 2011 Mar 1;3(3):1077.

Photo
Pravin Bhoyar
Corresponding author

Kamla Nehru College of Pharmacy Butibori, Nagpur Maharashtra (India)- 441108

Photo
Nitin Padole
Co-author

Kamla Nehru College of Pharmacy Butibori, Nagpur Maharashtra (India)- 441108

Photo
Nilakshi Dhoble
Co-author

Kamla Nehru College of Pharmacy Butibori, Nagpur Maharashtra (India)- 441108

Photo
Pankaj Dhapke
Co-author

Kamla Nehru College of Pharmacy Butibori, Nagpur Maharashtra (India)- 441108

Photo
Jagdish Baheti
Co-author

Kamla Nehru College of Pharmacy Butibori, Nagpur Maharashtra (India)- 441108

Pravin Bhoyar*, Nitin Padole, Nilakshi Dhoble, Pankaj Dhapke, Jagdish Baheti, Type ? Diabetes Mellitus and Their Managements, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 2, 1869-1880. https://doi.org/ 10.5281/zenodo.14913424

More related articles
Psoriasis: Comprehensive Review of Pathogenesis, C...
Neethu R , Dr.Rupesh pingale, Maseera Ashfeque chowguel, Vaishnav...
Integrating High-Sensitivity Troponin and Artifici...
Dr. Redlin Jani R.R, C. Rifa Sidhik Fathima, V. Sandhiya, C. Shif...
Therapeutic Potentials of Guggulu Formulations: A ...
Dr. Manasi D. Chunchuwar, Dr.Bharat Rathi, Dr.Piyush Chaudhary, D...
Phytoestrogenic And Therapeutic Potential of Clitoria Ternatea (Blue Pea) In Men...
Shweta Pandey, Nikita Pagare, Manisha Nangude, Akshata Palve, Sujal Nikam, Harshal Nathe, ...
Citrus Shield Vitamin C And E Enriched Skin Serum...
Harshal Deshmukh, Rakshada Dhudkekar, Dr. Swati Deshmukh, ...
Related Articles
Curcumin-Loaded In-Situ Gel for Ocular Complications in Diabetes Mellitus: A Nov...
Priti Singh , Piyush Biloniya , Anil Kumar , Prem Kumar , ...
Pharmacokinetics And Pharmacodynamics of Warfarin in Critically Ill Hematologica...
Rafael Pajaro Mojica, Luis Navarro Falx, Daniela Zuluaga Ramos, Luis Gutierrez Romero, Dayanna Maza ...
Vishwa Mukha Lepam Significant Role In Skin Complexion...
Vishakha Verma, Vaidhshiromani Dheeraj Sharma, Shekhar Solanki, Dr. M. K. Yadav, Dr. Ramakant Marde,...
Psoriasis: Comprehensive Review of Pathogenesis, Clinical Manifestations, and Ad...
Neethu R , Dr.Rupesh pingale, Maseera Ashfeque chowguel, Vaishnavi Sanjay chikhale, Tanishka tandel,...
More related articles
Psoriasis: Comprehensive Review of Pathogenesis, Clinical Manifestations, and Ad...
Neethu R , Dr.Rupesh pingale, Maseera Ashfeque chowguel, Vaishnavi Sanjay chikhale, Tanishka tandel,...
Integrating High-Sensitivity Troponin and Artificial Intelligence for Rapid Myoc...
Dr. Redlin Jani R.R, C. Rifa Sidhik Fathima, V. Sandhiya, C. Shifa Sidhiq Fatima, Y. Sneha, B. Rashm...
Therapeutic Potentials of Guggulu Formulations: A Review Through Medieval Centur...
Dr. Manasi D. Chunchuwar, Dr.Bharat Rathi, Dr.Piyush Chaudhary, Dr.Aditi R. Shinde, ...
Psoriasis: Comprehensive Review of Pathogenesis, Clinical Manifestations, and Ad...
Neethu R , Dr.Rupesh pingale, Maseera Ashfeque chowguel, Vaishnavi Sanjay chikhale, Tanishka tandel,...
Integrating High-Sensitivity Troponin and Artificial Intelligence for Rapid Myoc...
Dr. Redlin Jani R.R, C. Rifa Sidhik Fathima, V. Sandhiya, C. Shifa Sidhiq Fatima, Y. Sneha, B. Rashm...
Therapeutic Potentials of Guggulu Formulations: A Review Through Medieval Centur...
Dr. Manasi D. Chunchuwar, Dr.Bharat Rathi, Dr.Piyush Chaudhary, Dr.Aditi R. Shinde, ...